Physician profile
Frederick A Merrill
NPI 1740299650
$13,769.35
in general payments reported to CMS, 2019-2025
53 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,664 · 2020: $1,710 · 2021: $2,626 · 2022: $2,374 · 2023: $2,147 · 2024: $1,780 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,395.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,820.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,619.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $983.47 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $911.51 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $725.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $609.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $583.68 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $552.68 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $531.16 | 2021-2025 | |
| Pfizer INC. | $467.00 | 2019-2025 | |
| Abbott Laboratories | $424.34 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.42 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.44 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $320.80 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $264.03 | 2019-2024 | Verquvo, Belsomra, Capvaxive |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Merrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.